Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Debt Ratio (2022 - 2025)

Historic Debt Ratio for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 2.44.

  • BioXcel Therapeutics' Debt Ratio rose 1404.99% to 2.44 in Q3 2025 from the same period last year, while for Sep 2025 it was 2.44, marking a year-over-year increase of 1404.99%. This contributed to the annual value of 2.67 for FY2024, which is 9589.27% up from last year.
  • Per BioXcel Therapeutics' latest filing, its Debt Ratio stood at 2.44 for Q3 2025, which was up 1404.99% from 4.21 recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Debt Ratio peaked at 4.21 during Q2 2025, and registered a low of 0.0 during Q1 2022.
  • Moreover, its 4-year median value for Debt Ratio was 1.23 (2024), whereas its average is 1.44.
  • Its Debt Ratio has fluctuated over the past 5 years, first soared by 19961267.32% in 2023, then soared by 1404.99% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Debt Ratio stood at 0.45 in 2022, then soared by 200.59% to 1.36 in 2023, then surged by 95.89% to 2.67 in 2024, then decreased by 8.88% to 2.44 in 2025.
  • Its Debt Ratio was 2.44 in Q3 2025, compared to 4.21 in Q2 2025 and 2.74 in Q1 2025.